Matrix stiffness-regulated NSUN2 Increases HSP90AA1 expression to promote endoplasmic reticulum stress and hepatocellular carcinoma progression

Extracellular matrix (ECM) stiffness elevation, a prominent mechanical attribute in liver cirrhosis, is a key driver of hepatocellular carcinoma (HCC) progression. RNA 5-methylcytosine (m 5 C) modification regulates multiple RNA species to influence tumorigenesis, but its role in mechanotransduction—especially in response to matrix stiffness—remains unclear. Here, we found that increased matrix stiffness enhances HCC cell proliferation and metastasis, accompanied by elevated global m 5 C levels. High stiffness triggers autocrine transforming growth factor-β (TGF-β) secretion in HCC cells, which activates transcription factor Smad3 to upregulate NSUN2, a core m 5 C methyltransferase. Clinically, high NSUN2 expression and elevated m 5 C levels correlate with poor prognosis in HCC patients. Further studies showed NSUN2 directly binds to HSP90AA1 mRNA, enhances its m 5 C modification, and recruits the m 5 C reader ALYREF to stabilize HSP90AA1 mRNA. We also confirmed the matrix stiffness-NSUN2-HSP90AA1 axis activates endoplasmic reticulum (ER) stress, forming a pro-tumor cascade that promotes HCC growth and progression. Notably, we identified Vilanterol as a candidate NSUN2-targeting compound that effectively downregulates NSUN2 expression and global m 5 C levels and suppresses HCC malignant phenotypes. Collectively, our findings uncover a previously unrecognized regulatory axis, the matrix stiffness–NSUN2–HSP90AA1–ER stress axis, in HCC, and suggest that Vilanterol may serve as a promising therapeutic agent for HCC.

Authors

Institutions

Publication Details

Journal
Experimental Hematology and Oncology
Published
2026-11-21
DOI
https://doi.org/10.1186/s40164-026-00867-0
Primary Topic
RNA modifications and cancer
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Matrix stiffness-regulated NSUN2 Increases HSP90AA1 expression to promote endoplasmic reticulum stress and hepatocellular carcinoma progression

迟晓芹, 尹震宇, Chengrong Xie, 王付强 et al.
Experimental Hematology and Oncology
RNA modifications and cancer
article

Matrix stiffness-regulated NSUN2 Increases HSP90AA1 expression to promote endoplasmic reticulum stress and hepatocellular carcinoma progression

迟晓芹, 尹震宇, Chengrong Xie, 王付强, Changhong Luo, Yiwei Peng, Zhangquan Yang, Yuyan Lu, Xijun Chen, Yingcan Wu, Jing Wen, Yijia Shen, Lingyun Lin, Yu Sun, Jinzhu Wang
article en

Abstract

Extracellular matrix (ECM) stiffness elevation, a prominent mechanical attribute in liver cirrhosis, is a key driver of hepatocellular carcinoma (HCC) progression. RNA 5-methylcytosine (m 5 C) modification regulates multiple RNA species to influence tumorigenesis, but its role in mechanotransduction—especially in response to matrix stiffness—remains unclear. Here, we found that increased matrix stiffness enhances HCC cell proliferation and metastasis, accompanied by elevated global m 5 C levels. High stiffness triggers autocrine transforming growth factor-β (TGF-β) secretion in HCC cells, which activates transcription factor Smad3 to upregulate NSUN2, a core m 5 C methyltransferase. Clinically, high NSUN2 expression and elevated m 5 C levels correlate with poor prognosis in HCC patients. Further studies showed NSUN2 directly binds to HSP90AA1 mRNA, enhances its m 5 C modification, and recruits the m 5 C reader ALYREF to stabilize HSP90AA1 mRNA. We also confirmed the matrix stiffness-NSUN2-HSP90AA1 axis activates endoplasmic reticulum (ER) stress, forming a pro-tumor cascade that promotes HCC growth and progression. Notably, we identified Vilanterol as a candidate NSUN2-targeting compound that effectively downregulates NSUN2 expression and global m 5 C levels and suppresses HCC malignant phenotypes. Collectively, our findings uncover a previously unrecognized regulatory axis, the matrix stiffness–NSUN2–HSP90AA1–ER stress axis, in HCC, and suggest that Vilanterol may serve as a promising therapeutic agent for HCC.

Experimental Hematology and OncologyVol. 15(1)
Beijing University of Chinese Medicine (CN), Xiamen University (CN), University Medical Center Utrecht (NL), Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine (CN), Zhongshan Hospital of Xiamen University (CN), First Hospital of Jiaxing (CN)
RNA modifications and cancer
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon